MedTrace Logo

Clinical Performance of BioCLIA Ro60

NCT03204448 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-08-04

No results posted yet for this study

Summary

The study is to evaluate the clinical performance of BioCLIA Ro60 for measuring the autoantibody in autoimmune disease patients.

Conditions

Interventions

DEVICE

BioCLIA Ro60

BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL

Sponsors & Collaborators

  • HOB Biotech Group

    lead INDUSTRY

Principal Investigators

  • Polly Chan, PhD · CRM Biotech

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-08
Primary Completion
2020-04-16
Completion
2020-04-16
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03204448 on ClinicalTrials.gov